Clinical Trial Update: Symbicort Onset of Action 2 [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for Symbicort assessing onset of action in asthma; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Symbicort (budesonide/formoterol)

Snippet

Sponsor: AstraZeneca | Conditions: Asthma | Phase 3 | Status: COMPLETED